Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00606086 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of the Therapeutic Vaccine GI-5005 Combined With Pegylated Interferon Plus Ribavirin Standard of Care Therapy Versus Standard of Care Alone in Patients With Genotype 1 Chronic Hepatitis C Infection
A Phase 2 study, sponsored by GlobeImmune.
- Completed
- Registry status
- Phase 2
- Development phase
- 140
- Enrollment target
NCT00606086: Completed Phase 2 study, sponsored by GlobeImmune.
NCT00606086 is a Phase 2 study that has completed, run by GlobeImmune. The registered enrollment target is 140 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00606086, a Phase 2 study, has completed, sponsored by GlobeImmune.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 140 participants
- Enrollment target
Study Summary
The GI-5005 therapeutic vaccine in combination with standard of care or standard of care alone will be injected under the skin of HCV subjects. Patients will be monitored for safety, immune responses and any therapeutic benefits related to the injections including EVR, ETR, and SVR.
Primary Outcome
Early Virologic Response (EVR) is a response measured by the reduction of virus in the blood after 12 weeks of treatment.
Interventions
- DRUG GI-5005
- DRUG Pegylated Interferon and Ribavirin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2007-12 |
| Est. Completion | 2012-11 |
| Phase | Phase 2 |
What the finished NCT00606086 record still lists
NCT00606086 is an interventional study that assigns participants to a tested intervention. The registered 140 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which GI-5005 is the first listed.
NCT00606086 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00606086 about?
NCT00606086 is a clinical study titled "Safety and Efficacy of the Therapeutic Vaccine GI-5005 Combined With Pegylated Interferon Plus Ribavirin Standard of Care Therapy Versus Standard of Care Alone in Patients With Genotype 1 Chronic Hepatitis C Infection". The GI-5005 therapeutic vaccine in combination with standard of care or standard of care alone will be injected under the skin of HCV subjects. Patients will be monitored for safety, immune responses and any therapeutic benefits related to the injections including EVR, ETR, and SVR.
What is the current status of trial NCT00606086?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 140 participants. The study started on 2007-12. Estimated completion is 2012-11.
What interventions are being tested in trial NCT00606086?
The interventions under investigation include: GI-5005 (DRUG), Pegylated Interferon and Ribavirin (DRUG).
Who is sponsoring clinical trial NCT00606086?
This trial is sponsored by GlobeImmune, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00606086's enrollment target sits among peer trials
140 512th of 2000 higher than 1,476 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01419561 · 140 participants · Phase 2
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
- NCT01624805 · 140 participants · Phase 2
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
- NCT02369770 · 140 participants · NA
Sensory-Motor Rehabilitation Post Stroke
- NCT02455193 · 140 participants · NA
Neuronal Effects of Exercise in Schizophrenia
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia